Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial kinetoplast DNA (kDNA) is a massive, complex network of interlocked circular DNA molecules located within the single mitochondrion of kinetoplastid parasites, such as Leishmania and Trypanosoma species (Jensen, R. E., & Englund, P. T. (1998). The kinetoplast DNA of Trypanosoma brucei. Annual Review of Microbiology). This unique structure consists of two types of DNA: maxicircles, which encode essential mitochondrial proteins, and thousands of minicircles, which encode guide RNAs required for the extensive RNA editing of maxicircle transcripts (Shapiro, T. A., & Englund, P. T. (1995). The structure and replication of kinetoplast DNA. Annual Review of Microbiology). Because kDNA is vital for the parasite's energy metabolism and has no structural equivalent in mammalian cells, it is a highly selective target for chemotherapy (Cavalcanti, D. P., & de Souza, W. (2018). The Kinetoplast of Trypanosomatids. In: Trypanosomatids). Several clinically used drugs, including pentamidine and diminazene, are known to accumulate within the kinetoplast and bind to the minor groove of the DNA, leading to the condensation or loss of the kDNA network (Werbovetz, D. B. (2006). Diamidines as antitrypanosomal agents. Current Opinion in Investigational Drugs). The resulting "dyskinetoplasty" prevents the synthesis of functional mitochondrial enzymes, ultimately leading to parasite death. Consequently, kDNA remains a focal point for developing new treatments against diseases like leishmaniasis and Chagas disease.
Minor groove binding to AT-rich regions, inhibition of mitochondrial topoisomerase II, and induction of kDNA loss (dyskinetoplasty).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial kinetoplast DNA (kDNA) (kDNA).